Cargando…
Differences in the Intestinal Microbiome Associated with Diarrhea during Lenvatinib Treatment for Hepatocellular Carcinoma
INTRODUCTION: Lenvatinib has been widely used for the treatment of advanced hepatocellular carcinoma (HCC). Some adverse events, including diarrhea, have been reported for lenvatinib. Diarrhea may be associated with the changes in the intestinal microbiome; however, the underlying mechanism has not...
Autores principales: | Inukai, Yosuke, Yamamoto, Kenta, Honda, Takashi, Ito, Takanori, Imai, Norihiro, Ishizu, Yoji, Nakamura, Masanao, Kawashima, Hiroki, Ishigami, Masatoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909711/ https://www.ncbi.nlm.nih.gov/pubmed/35344958 http://dx.doi.org/10.1159/000524298 |
Ejemplares similares
-
Patients with low muscle mass have characteristic microbiome with low potential for amino acid synthesis in chronic liver disease
por: Yamamoto, Kenta, et al.
Publicado: (2022) -
Pretreatment Proteinuria Predicts the Prognosis of Patients Receiving Systemic Therapy for Unresectable Hepatocellular Carcinoma
por: Mizuno, Kazuyuki, et al.
Publicado: (2023) -
Pipeline Esophagogastric Varices Secondary to Extrahepatic Portal Vein Obstruction Treated Endoscopically with the Assistance of Transileocolic Obliteration
por: Yokoyama, Shinya, et al.
Publicado: (2022) -
Changes in the gut microbiota after hepatitis C virus eradication
por: Honda, Takashi, et al.
Publicado: (2021) -
Distinct features of two lipid droplets types in cell nuclei from patients with liver diseases
por: Imai, Norihiro, et al.
Publicado: (2023)